|
Market Cap (4-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 31 August 2022, 16:15. The announcement is marked as price sensitive, and is 2 page(s) in length and 244.24kb in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.071% short sold according to ASIC data. It was ranked the 492nd most shorted stock on the ASX. It is now ranked as the 455th most shorted stock on the ASX with 0.066% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Appendix 4E | 31 August 2022, 16:15 |
| Cleansing Statement | 22 August 2022, 16:17 |
| Application for quotation of securities - RCE | 22 August 2022, 16:11 |
| Phase I Clinical Trial of R327 I.V. - 6000mg Complete | 22 August 2022, 8:04 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 